ArticleChemistry & biodiversity2026
Chinese Yam Polysaccharide Ameliorates Obesity by Promoting Lipolysis Via the cAMP/PKA Signaling Pathway.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is associated with multiple health problems and has become a major public health challenge worldwide. In this study, the monosaccharide composition of CYP was determined using the PMP pre-column derivatization method. The results showed that CYP was composed of Glc, Gal, Ara, Man, and GlcA. In addition, the anti-obesity effects of CYP were evaluated using OP9 cells in vitro and a zebrafish obesity model in vivo. The findings revealed that CYP effectively promoted lipolysis, significantly modulated the expression of lipolysis-related proteins, and markedly reduced lipid accumulation in obese zebrafish. Subsequently, the potential molecular mechanism underlying the anti-obesity effects of CYP was explored via network pharmacology, molecular docking, and experimental validation. Protein-protein interaction network analysis identified five core targets, including STAT3, CASP3, PPARA, JUN, and MMP9. Moreover, KEGG enrichment analysis and molecular docking indicated that the cAMP signaling pathway may mediate the anti-obesity effects of CYP, with STAT3 serving as a potential therapeutic target. Furthermore, Western blot experiments demonstrated that CYP downregulated STAT3 expression and activated the cAMP/PKA signaling pathway, thereby ameliorating obesity. Collectively, these findings suggest that CYP holds promise as a novel anti-obesity agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.